X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TT-00420 (Tinengotinib), a next-generation FGFR inhibitor with high potency against a variety of FGFR2 kinase domain mutations, has shown promising clinical benefit in subjects with FGFR-altered metastatic CCA.
Lead Product(s): TT-00420
Therapeutic Area: Oncology Product Name: TT-00420
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2024
Details:
TT-02332 is a novel, highly potent and CNS-penetrating NLRP3 inhibitor. It is being evaluated for the treatment of obesity, inflammatory bowel disease & dermatitis.
Lead Product(s): TT-02332
Therapeutic Area: Nutrition and Weight Loss Product Name: TT-02332
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
TT-00420 (tinengotinib), which is an investigational next-generation FGFR inhibitor. currently, it is being evaluated in the Phase III clinical trial studies with patients for the treatment of advanced FGFR-altered cholangiocarcinoma.
Lead Product(s): TT-00420
Therapeutic Area: Oncology Product Name: TT-00420
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
TT-00420 is spectrum selective kinase inhibitor that is found to show high potency to a variety of clinically identified FGFR2 mutations in preclinical experiments. A large number of preclinical studies have found that TT-00420 has promising inhibitory effect on tumors.
Lead Product(s): TT-00420
Therapeutic Area: Oncology Product Name: TT-00420
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021
Details:
Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Teijin Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2020
Details:
Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025.
Lead Product(s): TT-01025
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TT-01025
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: LG Chem
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
